These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 21945262)

  • 1. Safety and immunogenicity of long HSV-2 peptides complexed with rhHsc70 in HSV-2 seropositive persons.
    Wald A; Koelle DM; Fife K; Warren T; Leclair K; Chicz RM; Monks S; Levey DL; Musselli C; Srivastava PK
    Vaccine; 2011 Nov; 29(47):8520-9. PubMed ID: 21945262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A heat shock protein based polyvalent vaccine targeting HSV-2: CD4(+) and CD8(+) cellular immunity and protective efficacy.
    Mo A; Musselli C; Chen H; Pappas J; Leclair K; Liu A; Chicz RM; Truneh A; Monks S; Levey DL; Srivastava PK
    Vaccine; 2011 Nov; 29(47):8530-41. PubMed ID: 21767588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic immunization with a mixture of herpes simplex virus 1 glycoprotein D-derived “asymptomatic” human CD8+ T-cell epitopes decreases spontaneous ocular shedding in latently infected HLA transgenic rabbits: association with low frequency of local PD-1+ TIM-3+ CD8+ exhausted T cells.
    Khan AA; Srivastava R; Chentoufi AA; Geertsema R; Thai NT; Dasgupta G; Osorio N; Kalantari M; Nesburn AB; Wechsler SL; BenMohamed L
    J Virol; 2015 Jul; 89(13):6619-32. PubMed ID: 25878105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs.
    Hoshino Y; Dalai SK; Wang K; Pesnicak L; Lau TY; Knipe DM; Cohen JI; Straus SE
    J Virol; 2005 Jan; 79(1):410-8. PubMed ID: 15596834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic Mucosal Vaccination of Herpes Simplex Virus 2-Infected Guinea Pigs with Ribonucleotide Reductase 2 (RR2) Protein Boosts Antiviral Neutralizing Antibodies and Local Tissue-Resident CD4
    Srivastava R; Roy S; Coulon PG; Vahed H; Prakash S; Dhanushkodi N; Kim GJ; Fouladi MA; Campo J; Teng AA; Liang X; Schaefer H; BenMohamed L
    J Virol; 2019 May; 93(9):. PubMed ID: 30787156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel HSV-2 subunit vaccine induces GLA-dependent CD4 and CD8 T cell responses and protective immunity in mice and guinea pigs.
    Odegard JM; Flynn PA; Campbell DJ; Robbins SH; Dong L; Wang K; Ter Meulen J; Cohen JI; Koelle DM
    Vaccine; 2016 Jan; 34(1):101-9. PubMed ID: 26571309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity, protective efficacy, and non-replicative status of the HSV-2 vaccine candidate HSV529 in mice and guinea pigs.
    Bernard MC; Barban V; Pradezynski F; de Montfort A; Ryall R; Caillet C; Londono-Hayes P
    PLoS One; 2015; 10(4):e0121518. PubMed ID: 25837802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Laser Adjuvant-Assisted Peptide Vaccine Promotes Skin Mobilization of Dendritic Cells and Enhances Protective CD8
    Lopes PP; Todorov G; Pham TT; Nesburn AB; Bahraoui E; BenMohamed L
    J Virol; 2018 Apr; 92(8):. PubMed ID: 29437976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective immunity to genital herpes simplex virus type 1 and type 2 provided by self-adjuvanting lipopeptides that drive dendritic cell maturation and elicit a polarized Th1 immune response.
    Bettahi I; Zhang X; Afifi RE; BenMohamed L
    Viral Immunol; 2006; 19(2):220-36. PubMed ID: 16817765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination with the Secreted Glycoprotein G of Herpes Simplex Virus 2 Induces Protective Immunity after Genital Infection.
    Önnheim K; Ekblad M; Görander S; Bergström T; Liljeqvist JÅ
    Viruses; 2016 Apr; 8(4):110. PubMed ID: 27110813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a therapeutic vaccine for HSV-2.
    Hosken NA
    Vaccine; 2005 Mar; 23(17-18):2395-8. PubMed ID: 15755634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I dose-escalation study of a monovalent heat shock protein 70-herpes simplex virus type 2 (HSV-2) peptide-based vaccine designed to prime or boost CD8 T-cell responses in HSV-naïve and HSV-2-infected subjects.
    Koelle DM; Magaret A; McClurkan CL; Remington ML; Warren T; Teofilovici F; Wald A
    Clin Vaccine Immunol; 2008 May; 15(5):773-82. PubMed ID: 18353920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of different forms of herpes simplex replication-defective mutant viruses as vaccines in a mouse model of HSV-2 genital infection.
    Da Costa XJ; Morrison LA; Knipe DM
    Virology; 2001 Sep; 288(2):256-63. PubMed ID: 11601897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune responses elicited by the GEN-003 candidate HSV-2 therapeutic vaccine in a randomized controlled dose-ranging phase 1/2a trial.
    Flechtner JB; Long D; Larson S; Clemens V; Baccari A; Kien L; Chan J; Skoberne M; Brudner M; Hetherington S
    Vaccine; 2016 Oct; 34(44):5314-5320. PubMed ID: 27642130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nasal and skin delivery of IC31(®)-adjuvanted recombinant HSV-2 gD protein confers protection against genital herpes.
    Wizel B; Persson J; Thörn K; Nagy E; Harandi AM
    Vaccine; 2012 Jun; 30(29):4361-8. PubMed ID: 22682292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycoprotein-D-adjuvant vaccine to prevent genital herpes.
    Stanberry LR; Spruance SL; Cunningham AL; Bernstein DI; Mindel A; Sacks S; Tyring S; Aoki FY; Slaoui M; Denis M; Vandepapeliere P; Dubin G;
    N Engl J Med; 2002 Nov; 347(21):1652-61. PubMed ID: 12444179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of glycoprotein D-adjuvant genital herpes vaccine.
    Bernstein DI; Aoki FY; Tyring SK; Stanberry LR; St-Pierre C; Shafran SD; Leroux-Roels G; Van Herck K; Bollaerts A; Dubin G;
    Clin Infect Dis; 2005 May; 40(9):1271-81. PubMed ID: 15825029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A vaccine containing highly purified virus particles in adjuvant provides high level protection against genital infection and disease in guinea pigs challenged intravaginally with homologous and heterologous strains of herpes simplex virus type 2.
    Bernstein DI; Morello CS; Cardin RD; Bravo FJ; Kraynyak KA; Spector DH
    Vaccine; 2020 Jan; 38(1):79-89. PubMed ID: 31611098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Herpes simplex virus antigens directly activate NK cells via TLR2, thus facilitating their presentation to CD4 T lymphocytes.
    Kim M; Osborne NR; Zeng W; Donaghy H; McKinnon K; Jackson DC; Cunningham AL
    J Immunol; 2012 May; 188(9):4158-70. PubMed ID: 22467654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines.
    Stanberry LR
    Herpes; 2004 Aug; 11 Suppl 3():161A-169A. PubMed ID: 15319086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.